KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
Ideaya's conjugate journey continues
The synthetic lethality specialist licenses in its second ADC in six months.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
Ideaya eyes neoadjuvant uveal melanoma
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
Replimune goes pivotal in uveal melanoma
The group eyes a broader use than Immunocore’s Kimmtrak.
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
